Crescent Enterprises’ CE-Ventures backs Aptadir Therapeutics in €40 million seed round
CE-Ventures invested in Aptadir Therapeutics’ €40 million seed round announced Sept. 29, 2026, targeting CAP1-FMR1 for Fragile X Syndrome and other programs.
CE-Ventures invested in Aptadir Therapeutics’ €40 million seed round announced Sept. 29, 2026, targeting CAP1-FMR1 for Fragile X Syndrome and other programs.